The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2020 Dec 1

PMID 33258950

Citations 11

Authors

Melissa S Putman

Logan B Greenblatt

Michael Bruce

Taisha Joseph

Hang Lee

Gregory Sawicki

Ahmet Uluer

Leonard Sicilian

Isabel Neuringer

Catherine M Gordon

Mary L Bouxsein

Joel S Finkelstein

Affiliations

Soon will be listed here.

Abstract

Context: Cystic fibrosis (CF) transmembrane conductance (CFTR) dysfunction may play a role in CF-related bone disease (CFBD). Ivacaftor is a CFTR potentiator effective in improving pulmonary and nutritional outcomes in patients with the G551D-CFTR mutation. The effects of ivacaftor on bone health are unknown.

Objective: To determine the impact of ivacaftor on bone density and microarchitecture in children and adults with CF.

Design: Prospective observational multiple cohort study.

Setting: Outpatient clinical research center within a tertiary academic medical center.

Patients Or Other Participants: Three cohorts of age-, race-, and gender-matched subjects were enrolled: 26 subjects (15 adults and 11 children) with CF and the G551D-CFTR mutation who were planning to start or had started treatment with ivacaftor within 3 months (Ivacaftor cohort), 26 subjects with CF were not treated with ivacaftor (CF Control cohort), and 26 healthy volunteers.

Interventions: All treatments, including Ivacaftor, were managed by the subjects' pulmonologists.

Main Outcome Measures: Bone microarchitecture by high-resolution peripheral quantitative computed tomography (HR-pQCT), areal bone mineral density (aBMD) by dual-energy X-ray absorptiometry (DXA) and bone turnover markers at baseline, 1, and 2 years.

Results: Cortical volume, area, and porosity at the radius and tibia increased significantly in adults in the Ivacaftor cohort. No significant differences were observed in changes in aBMD, trabecular microarchitecture, or estimated bone strength in adults or in any outcome measures in children.

Conclusions: Treatment with ivacaftor was associated with increases in cortical microarchitecture in adults with CF. Further studies are needed to understand the implications of these findings.

Citing Articles

Longitudinal changes in BMD in adults with cystic fibrosis.

Jad R, Ma X, Stanojevic S, Illango A, Tullis E, Gilmour J J Bone Miner Res. 2024; 39(12):1716-1721.

PMID: 39221749 PMC: 11637762. DOI: 10.1093/jbmr/zjae139.

Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond.

Mall M, Criner G, Miravitlles M, Rowe S, Vogelmeier C, Rowlands D Eur Respir J. 2023; 61(4).

PMID: 37003609 PMC: 10066568. DOI: 10.1183/13993003.01307-2022.

Cystic Fibrosis Bone Disease: The Interplay between CFTR Dysfunction and Chronic Inflammation.

Fonseca O, Gomes M, Amorim M, Gomes A Biomolecules. 2023; 13(3).

PMID: 36979360 PMC: 10046889. DOI: 10.3390/biom13030425.

Prevalence and Risk Factors for Low Bone Mineral Density in Adults With Cystic Fibrosis.

Boyle R, Psoter K, Merlo C, Sidhaye A, Lechtzin N, Patel S JBMR Plus. 2022; 6(11):e10666.

PMID: 36398108 PMC: 9664525. DOI: 10.1002/jbm4.10666.

Effect of Trikafta on bone density, body composition and exercise capacity in CF: A pilot study.

Gur M, Bar-Yoseph R, Hanna M, Abboud D, Keidar Z, Palchan T Pediatr Pulmonol. 2022; 58(2):577-584.

PMID: 36372909 PMC: 10100338. DOI: 10.1002/ppul.26243.

References

Aris R, ONTJES D, Buell H, Blackwood A, Lark R, Caminiti M . Abnormal bone turnover in cystic fibrosis adults. Osteoporos Int. 2002; 13(2):151-7. DOI: 10.1007/s001980200007. View

Vilayphiou N, Boutroy S, Sornay-Rendu E, van Rietbergen B, Chapurlat R . Age-related changes in bone strength from HR-pQCT derived microarchitectural parameters with an emphasis on the role of cortical porosity. Bone. 2015; 83:233-240. DOI: 10.1016/j.bone.2015.10.012. View

Sermet-Gaudelus I, Delion M, Durieu I, Jacquot J, Hubert D . Bone demineralization is improved by ivacaftor in patients with cystic fibrosis carrying the p.Gly551Asp mutation. J Cyst Fibros. 2016; 15(6):e67-e69. DOI: 10.1016/j.jcf.2016.09.003. View

Macneil J, Boyd S . Accuracy of high-resolution peripheral quantitative computed tomography for measurement of bone quality. Med Eng Phys. 2007; 29(10):1096-105. DOI: 10.1016/j.medengphy.2006.11.002. View

Pashuck T, Franz S, Altman M, Wasserfall C, Atkinson M, Wronski T . Murine model for cystic fibrosis bone disease demonstrates osteopenia and sex-related differences in bone formation. Pediatr Res. 2008; 65(3):311-6. PMC: 4201032. DOI: 10.1203/PDR.0b013e3181961e80. View

Kelly A, Shults J, Mostoufi-Moab S, McCormack S, Stallings V, Schall J . Pediatric Bone Mineral Accrual Z-Score Calculation Equations and Their Application in Childhood Disease. J Bone Miner Res. 2018; 34(1):195-203. PMC: 7794655. DOI: 10.1002/jbmr.3589. View

Legroux-Gerot I, Leroy S, Prudhomme C, Perez T, Flipo R, Wallaert B . Bone loss in adults with cystic fibrosis: prevalence, associated factors, and usefulness of biological markers. Joint Bone Spine. 2011; 79(1):73-7. DOI: 10.1016/j.jbspin.2011.05.009. View

Tsai J, Uihlein A, Burnett-Bowie S, Neer R, Derrico N, Lee H . Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study). J Clin Endocrinol Metab. 2016; 101(5):2023-30. PMC: 4870854. DOI: 10.1210/jc.2016-1160. View

Gensburger D, Boutroy S, Chapurlat R, Nove-Josserand R, Roche S, Rabilloud M . Reduced bone volumetric density and weak correlation between infection and bone markers in cystic fibrosis adult patients. Osteoporos Int. 2016; 27(9):2803-2813. DOI: 10.1007/s00198-016-3612-9. View

10.

Stalvey M, Clines K, Havasi V, McKibbin C, Dunn L, Chung W . Osteoblast CFTR inactivation reduces differentiation and osteoprotegerin expression in a mouse model of cystic fibrosis-related bone disease. PLoS One. 2013; 8(11):e80098. PMC: 3827431. DOI: 10.1371/journal.pone.0080098. View

11.

Paccou J, Zeboulon N, Combescure C, Gossec L, Cortet B . The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis. Calcif Tissue Int. 2009; 86(1):1-7. DOI: 10.1007/s00223-009-9316-9. View

12.

Sievert Y, Schakel S, Buzzard I . Maintenance of a nutrient database for clinical trials. Control Clin Trials. 1989; 10(4):416-25. DOI: 10.1016/0197-2456(89)90006-8. View

13.

Cobanoglu N, Atasoy H, Ozcelik U, Yalcin E, Dogru D, Kiper N . Relation of bone mineral density with clinical and laboratory parameters in pre-pubertal children with cystic fibrosis. Pediatr Pulmonol. 2009; 44(7):706-12. DOI: 10.1002/ppul.21050. View

14.

Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W . Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009; 32(9):1626-31. PMC: 2732133. DOI: 10.2337/dc09-0586. View

15.

Vilayphiou N, Boutroy S, Szulc P, van Rietbergen B, Munoz F, Delmas P . Finite element analysis performed on radius and tibia HR-pQCT images and fragility fractures at all sites in men. J Bone Miner Res. 2011; 26(5):965-73. DOI: 10.1002/jbmr.297. View

16.

Aris R, Renner J, Winders A, Buell H, Riggs D, Lester G . Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann Intern Med. 1998; 128(3):186-93. DOI: 10.7326/0003-4819-128-3-199802010-00004. View

17.

Liu D, Burrows M, Egeli D, McKay H . Site specificity of bone architecture between the distal radius and distal tibia in children and adolescents: An HR-pQCT study. Calcif Tissue Int. 2010; 87(4):314-23. DOI: 10.1007/s00223-010-9405-9. View

18.

Henderson R, Specter B . Kyphosis and fractures in children and young adults with cystic fibrosis. J Pediatr. 1994; 125(2):208-12. DOI: 10.1016/s0022-3476(94)70194-6. View

19.

Bala Y, Zebaze R, Ghasem-Zadeh A, Atkinson E, Iuliano S, Peterson J . Cortical porosity identifies women with osteopenia at increased risk for forearm fractures. J Bone Miner Res. 2014; 29(6):1356-62. PMC: 4156822. DOI: 10.1002/jbmr.2167. View

20.

Le Heron L, Guillaume C, Velard F, Braux J, Touqui L, Moriceau S . Cystic fibrosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) E2 in human bone. J Cyst Fibros. 2009; 9(1):69-72. DOI: 10.1016/j.jcf.2009.11.005. View